针对阿尔茨海默病的粉样蛋白降低免疫疗法:目前的状况和未来的方向
Michael S Rafii1, Paul S Aisen2
1Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA. mrafii@usc.edu.
新的阿尔茨海默病 (AD) 治疗方法,特别是粉样蛋白降低单克隆抗体 (mAbs),显著降低大脑粉样蛋白β水平并减缓认知衰退. 这标志着在所有疾病阶段的AD管理中开启了一个新时代.
科学领域:
- 神经学 神经学
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 随着疾病修饰疗法的出现,阿尔茨海默病 (AD) 管理正在不断发展.
- 批准的第一个改变疾病的疗法是针对粉样蛋白β (Aβ) 的免疫疗法.
研究的目的:
- 对阿尔茨海默病的amyloid降低单克隆抗体 (mAb) 疗法的进展进行审查.
- 探索AD治疗和临床整合的未来方向.
- 讨论AD作为生物连续性及其对治疗评估的影响.
主要方法:
- 对粉样蛋白降低mAbs.最近的临床试验数据的审查.
- 对AD病理生理学及其连续性的分析.
- 检查影响临床实践整合的因素.
主要成果:
- 粉样蛋白降低的mAbs大大降低了大脑的Aβ水平.
- 这些疗法在大型试验中证明了认知和临床衰退的减缓.
- 已经建立了一个概念框架来评估整个AD频谱的mAbs.
结论:
- 具有里程碑意义的批准标志着阿尔茨海默病治疗的新时代.
- 粉样蛋白降低的mAbs在AD连续体中提供疾病修饰的好处.
- 整合到临床实践中需要仔细考虑各种因素.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Microorganisms in Medicine and Therapeutics
Atherosclerosis III: Management
Targeted Cancer Therapies
There are several types of targeted therapies against...
